FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2948816616> ?p ?o ?g. }

• W2948816616 endingPage "787" @default.
• W2948816616 startingPage "787" @default.
• W2948816616 abstract "Several new multikinase inhibitors have recently been introduced into clinical practice for hepatocellular carcinoma (HCC) therapy. Small increases in survival were reported as well as considerable toxicity. There is thus a need for effective therapies with lower toxicities. We examined whether a combination of sorafenib and regorafenib might also be effective at very low concentrations, with resulting potential for lessened clinical toxicity. MTT test, clonogenic assay, Ki67 staining and cell cycle analysis were assessed for cell proliferation and Annexin V and western blotting analysis relative to the expression of cleaved Caspase-3 and BID for cell apoptosis. In these experimental conditions cell growth and migration were potently inhibited and apoptosis induced even in HCC cells producing high alpha fetoprotein (AFP) levels (clinically worse prognosis). The combination also inhibited levels of the two HCC biomarkers, AFP and des gamma carboxy prothrombin (DCP). Additional inhibition of Vascular Endothelial Growth Factor Receptor (VEGFR) or Insulin-like Growth Factor 1 Receptor (IGF1R) enhanced effects on AFP and DCP levels, cell growth inhibition and MAPK and PI3K/Akt signaling inhibition due to sorafenib/regorafenib combination. These combinations have the potential for decreased toxicity while simultaneously enhancing therapeutic effects. This potential decrease in toxicity is being explored in ongoing studies." @default.
• W2948816616 created "2019-06-14" @default.
• W2948816616 creator A5004073983 @default.
• W2948816616 creator A5009618182 @default.
• W2948816616 creator A5025644297 @default.
• W2948816616 creator A5041373096 @default.
• W2948816616 creator A5052303723 @default.
• W2948816616 creator A5067576970 @default.
• W2948816616 date "2019-06-07" @default.
• W2948816616 modified "2023-10-18" @default.
• W2948816616 title "Ramucirumab and GSK1838705A Enhance the Inhibitory Effects of Low Concentration Sorafenib and Regorafenib Combination on HCC Cell Growth and Motility" @default.
• W2948816616 cites W114670131 @default.
• W2948816616 cites W1968209756 @default.
• W2948816616 cites W1968490444 @default.
• W2948816616 cites W1971837077 @default.
• W2948816616 cites W1990620476 @default.
• W2948816616 cites W2010011145 @default.
• W2948816616 cites W2049388837 @default.
• W2948816616 cites W2061345986 @default.
• W2948816616 cites W2068382946 @default.
• W2948816616 cites W2077945404 @default.
• W2948816616 cites W2096129191 @default.
• W2948816616 cites W2102942095 @default.
• W2948816616 cites W2140765540 @default.
• W2948816616 cites W2141358606 @default.
• W2948816616 cites W2149951854 @default.
• W2948816616 cites W2167367321 @default.
• W2948816616 cites W2248222708 @default.
• W2948816616 cites W2253140379 @default.
• W2948816616 cites W2263171370 @default.
• W2948816616 cites W2339286393 @default.
• W2948816616 cites W2465259064 @default.
• W2948816616 cites W2560499218 @default.
• W2948816616 cites W2590313461 @default.
• W2948816616 cites W2759365306 @default.
• W2948816616 cites W2787358630 @default.
• W2948816616 cites W2793403000 @default.
• W2948816616 cites W2796121377 @default.
• W2948816616 cites W2804160141 @default.
• W2948816616 cites W2883204623 @default.
• W2948816616 cites W2885234188 @default.
• W2948816616 cites W4252851641 @default.
• W2948816616 doi "https://doi.org/10.3390/cancers11060787" @default.
• W2948816616 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6627995" @default.
• W2948816616 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/31181647" @default.
• W2948816616 hasPublicationYear "2019" @default.
• W2948816616 type Work @default.
• W2948816616 sameAs 2948816616 @default.
• W2948816616 citedByCount "8" @default.
• W2948816616 countsByYear W29488166162020 @default.
• W2948816616 countsByYear W29488166162021 @default.
• W2948816616 countsByYear W29488166162022 @default.
• W2948816616 crossrefType "journal-article" @default.
• W2948816616 hasAuthorship W2948816616A5004073983 @default.
• W2948816616 hasAuthorship W2948816616A5009618182 @default.
• W2948816616 hasAuthorship W2948816616A5025644297 @default.
• W2948816616 hasAuthorship W2948816616A5041373096 @default.
• W2948816616 hasAuthorship W2948816616A5052303723 @default.
• W2948816616 hasAuthorship W2948816616A5067576970 @default.
• W2948816616 hasBestOaLocation W29488166161 @default.
• W2948816616 hasConcept C117262875 @default.
• W2948816616 hasConcept C121608353 @default.
• W2948816616 hasConcept C126322002 @default.
• W2948816616 hasConcept C185592680 @default.
• W2948816616 hasConcept C190283241 @default.
• W2948816616 hasConcept C2776248978 @default.
• W2948816616 hasConcept C2778019345 @default.
• W2948816616 hasConcept C2778695046 @default.
• W2948816616 hasConcept C29537977 @default.
• W2948816616 hasConcept C29730261 @default.
• W2948816616 hasConcept C502942594 @default.
• W2948816616 hasConcept C526805850 @default.
• W2948816616 hasConcept C55493867 @default.
• W2948816616 hasConcept C57074206 @default.
• W2948816616 hasConcept C62112901 @default.
• W2948816616 hasConcept C62478195 @default.
• W2948816616 hasConcept C71924100 @default.
• W2948816616 hasConcept C75217442 @default.
• W2948816616 hasConcept C98274493 @default.
• W2948816616 hasConceptScore W2948816616C117262875 @default.
• W2948816616 hasConceptScore W2948816616C121608353 @default.
• W2948816616 hasConceptScore W2948816616C126322002 @default.
• W2948816616 hasConceptScore W2948816616C185592680 @default.
• W2948816616 hasConceptScore W2948816616C190283241 @default.
• W2948816616 hasConceptScore W2948816616C2776248978 @default.
• W2948816616 hasConceptScore W2948816616C2778019345 @default.
• W2948816616 hasConceptScore W2948816616C2778695046 @default.
• W2948816616 hasConceptScore W2948816616C29537977 @default.
• W2948816616 hasConceptScore W2948816616C29730261 @default.
• W2948816616 hasConceptScore W2948816616C502942594 @default.
• W2948816616 hasConceptScore W2948816616C526805850 @default.
• W2948816616 hasConceptScore W2948816616C55493867 @default.
• W2948816616 hasConceptScore W2948816616C57074206 @default.
• W2948816616 hasConceptScore W2948816616C62112901 @default.
• W2948816616 hasConceptScore W2948816616C62478195 @default.
• W2948816616 hasConceptScore W2948816616C71924100 @default.
• W2948816616 hasConceptScore W2948816616C75217442 @default.
• W2948816616 hasConceptScore W2948816616C98274493 @default.

• next